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Objective: Diabetes has not yet been investigated as a risk factor for early and late
cardiac-related death.
Methods: Patients operated on from January 1988 to December 1999 were consid-
ered; 767 were diabetic (group D) and 2593 were nondiabetic (group ND). Patients
with preoperative hemodynamic deterioration were excluded. Early (30-day) mor-
tality (any causes and cardiac causes) was evaluated with univariate analysis and
stepwise logistic regression. Ten-year actuarial freedom from death of any cause and
cardiac death was also assessed with univariate and Cox analyses.
Results: Early mortality was 2.2% (group D, 3.3%; group ND, 1.9%; P  .023).
Early cardiac mortality was 1.3% (group D, 2.2%; group ND, 1.1%; P  .0016).
Diabetes was an independent risk factor only for cardiac death and not for death of
any cause. Five-year survival was 93.5%  0.5% (group D, 92.5%  1.1%; group
ND, 93.9%  0.6%; P  .0304). Diabetes was not an independent risk factor.
Five-year freedom for cardiac death was 96.3%  0.4% (group D, 94.9%  0.9%;
group ND, 96.6%  0.4%; P  .0155). Diabetes was an independent risk factor.
However, if only the patients who survived the first 30 days are considered, diabetes
disappears as a risk factor (5-year freedom for cardiac death, 97.8%  0.3%; group
D, 97.3%  0.8%; group ND, 97.9%  0.4%; P  0.2389).
Conclusions: Diabetes is an independent risk factor for early cardiac death only.
Long-term survival in patients who survive the first 30 days is not statistically
significantly different for diabetic and nondiabetic patients. In fact, the rates appear
very similar.
Diabetes is a widely recognized risk factor for increased early andlate mortality after myocardial revascularization in patients withmultivessel disease.1-17 Even if better results after coronary arterybypass grafting (CABG) than after percutaneous transluminalcoronary angioplasty had been demonstrated in the Bypass An-gioplasty Revascularization Investigation trial,1 further studies
were not able to confirm this finding.13,14 Therefore it seems that diabetes is a risk
factor independent from the strategy used. However, in other studies diabetes seems
to be weakly related to higher early and late mortality after CABG,15-22 leaving the
problem open to further evaluation.
During the past decade, different surgical techniques, such as normothermic
perfusion,23 CABG on a beating heart without cardiopulmonary bypass (CPB),24,25
and extensive use of arterial conduits,26,27 became popular. We reviewed our
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experience in patients with multivessel coronary disease
who underwent surgical revascularization during a 12-year
period to evaluate (1) whether diabetes is a risk factor for
early or late survival and, if so, (2) whether there is any
technical factor that can improve survival in diabetic pa-
tients.
Methods
From January 1988 to December 1999, 3392 patients with mul-
tivessel disease underwent first isolated surgical myocardial revas-
cularization. Thirty-two patients who had preoperative low-output
syndrome were not included because their status could influence
the early outcome more than any other risk factor. Globally, 3360
patients were entered into this study. Among them, 767 patients
(22.8%) were diabetic (group D) and receiving oral (group OT,
n  596 [77.7%]) or insulin (group IT, n  171 [22.3%]) treat-
ment, and 2593 (77.2%) were nondiabetic (group ND). Patients on
diet because of mild fasting hyperglycemia were considered in
group ND. Table 1 shows some of the preoperative characteristics
of both groups.
Surgical Details
CPB was used in 2181 (65.4%) patients and not used in 1179
(34.6%) patients. Perioperative technical data are shown in Table
2. Simultaneous carotid endoarterectomy was performed in 65
patients (1.9%; 47 [1.8%] in group ND and 18 [2.3%] in group D;
P  .345).
Postoperative Course
After the operation, all the patients were admitted to the intensive
care unit and later sent to the regular ward. They were then
followed up at our outpatient clinic. The follow-up deadline was
June 30, 2000. Recent information about their clinical status was
obtained directly from the referring physician or by telephone.
Mean follow-up was 50  38 months (median, 41 months; min-
imum, 3 months; maximum, 150 months; 25th percentile, 20
months; 75th percentiles, 67 months), 43  34 months in diabetic
patients (median, 33 months; minimum, 3 months; maximum, 149
months; 25th percentile, 17 months; 75th percentile, 67 months),
and 53  39 months in nondiabetic patients (median, 44 months;
minimum, 3 months; maximum, 150 months; 25th percentile, 21
months; 75th percentile, 72 months; P  .001). Follow-up was
98.9% completed.
Study Method
The real survival at 30 days after the operation was analyzed by
using a variety of risk factors (appendix). Patients were first
considered as a whole; as a second step, rates were given overall
and by diabetes group to illustrate the association of factors on
outcomes within the patients in groups D and ND.
The same variables were used to analyze 5-year actuarial
survival, inclusive of the first month, for all patients. As a second
step, the first month was withdrawn from the analysis, and the
5-year survival of patients who survived 1 month was evaluated to
explore the weight of early mortality on late survival. All the
analyses were repeated to evaluate the influence of diabetes on
freedom from cardiac death. When some perioperative surgical
strategies were evaluated, survival and freedom from cardiac death
were considered at 10 years.
Definitions of Terms
Need of inotropic agents was defined as infusion of greater than 5
g  kg1  min1 dobutamine or any dose of epinephrine or
norepinephrine for more than 12 hours.
Cerebrovascular accident (CVA) was defined as global or
focal neurologic deficit lasting less (transient ischemic attack) or
more (stroke) than 24 hours that could be evident after emergence
from anesthesia or after first awaking without any neurologic
deficits. CVA was diagnosed by a neurologist and confirmed with
a brain computed tomographic scan.
Acute myocardial infarction was defined as enzymatic eleva-
tion, electrocardiographic signs of necrosis, new akinetic segments
at echocardiography, and non–K-related ventricular arrhythmias.
Acute renal failure was defined as a postoperative creatinine
value of greater than 2.0 mg/dL for more than 24 hours if the
preoperative value was less than 1.4 mg/dL or a 1-unit creatinine
increase if the preoperative value was greater than 2.0 mg/dL.
Early major events were defined as the sum of death of any
cause, CVA, acute myocardial infarction, low-output syndrome
(defined as need for an intra-aortic balloon pump, inotropic drugs
TABLE 1. Preoperative data in diabetic (group D) and nondiabetic (group ND) patients
Group ND
(n  2593)
Group D
(n  767) P value
Age (y) 62.0 9.5 63.2 8.8 .001
75 217 (8.4%) 58 (7.6%) .474
EF (%) 59.1 12.9 57.0 14.0 .001
35 133 (5.1%) 62 (8.1%) .002
Female sex 327 (12.6%) 206 (26.9%) .001
Urgent 678 (26.1%) 209 (27.2%) .543
Left main 309 (11.9%) 88 (11.5%) .817
Hypertension 1133 (43.7%) 402 (52.4%) .001
Previous AMI 1445 (55.7%) 454 (59.2%) .407
Carotid disease 278 (10.7%) 128 (16.7%) .001
CRF (cr 2.0 mg/dL) 38 (1.5%) 14 (1.8%) .478
CHF 49 (1.9%) 23 (3.0%) .062
EF, Ejection fraction; AMI, acute myocardial infarction; CRF, chronic renal failure; cr, creatininemia; CHF, chronic heart failure.
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for 12 hours, or both), need for mechanical ventilation for more
than 24 hours in the absence of low-output syndrome, acute renal
insufficiency (defined as blood creatinine level 2.0 mg/dL and 2
times the preoperative value), or acute renal failure (need for
ultrafiltration without a related operation), gastrointestinal compli-
cations with or without related surgery.
Cardiac death was defined as any cardiac-related death, sudden
and unknown.
Statistical Analysis
All continuos variables were expressed as means  SD. Groups
were compared by means of unpaired 2-tailed t testing in case of
normally distributed factors, whereas Mann-Whitney tests were
used in case of nonnormally distributed variables, and 2 tests
(Pearson 2 and Fisher exact tests) were used for categoric vari-
ables. Stepwise logistic regression was used to select the indepen-
dent variables that could predict death of any cause. Actuarial
survival curves were obtained with the Kaplan-Meier method.
Statistical significance was calculated with the log-rank test. Cox
analysis was used to evaluate the independent risk factors for
reduced late survival. All the multivariable analysis included uni-
variate variables with P values of less than .2. Results of stepwise
logistic regression were expressed as odds ratios with associated
95% confidence limits and P values. Results of Cox analysis were
expressed as hazard ratios, 95% confidence limits, and P values.
The SPSS software (SPSS, Chicago, Ill) was used for all analyses
in this study.
Results
Early Mortality
During the first 30 days after the operation, 72 (2.2%)
patients died, 25 (3.3%) in group D and 49 (1.9%) in group
ND (P  .023). Table 3 summarizes the postoperative data.
The results of stepwise logistic regression are shown in
Table 4. Diabetes was not a risk factor for higher 30-day
mortality.
The incidence of cardiac-related 30-day mortality was
1.3% (45 patients), 2.2% (17 patients) in group D and 1.1%
(28 patients) in group ND (P  .016). The incidence of
cardiac deaths was higher in group D (17/25 [68.0%]) than
in group ND (28/49 [57.1%]) but not significantly (P 
.511). Results of stepwise logistic regression are also sum-
marized in Table 4. The analysis showed that diabetes was
an independent factor for increased 30-day cardiac-related
mortality. Again, early survival was not influenced by any
technical aspect.
Late Actuarial Survival
During the follow-up period, 137 (4.1%) patients died, 32
(4.2%) in group D and 105 (4.0%) in group ND. Five-year
overall actuarial survival, first month included, was 93.5%
 0.5%, 93.9%  0.6% in group ND and 92.5%  1.1% in
group D (P  .0304, Figure 1). Table 5 shows the indepen-
dent predictors of lower survival at the Cox analysis. Diabetes
was not an independent predictor of higher late mortality.
Seventy-three (2.2%) patients died of cardiac causes, 20
(2.6%) in group D and 53 (2.0%) in group ND. The inci-
dence for cardiac death was higher in group D (20/32
[62.5%]) than in group ND (53/105 [50.5%]). Freedom
from cardiac death, first month included, was 96.3% 
TABLE 3. Early postoperative data according to groups ND
and D
Group ND
(n  2593)
Group D
(n  767) P value
Deaths 49 (1.9%) 25 (3.3%) .023
CVA 29 (2.1%) 8 (1.0%) .861
AMI 23 (0.9%) 8 (1.0%) .089
Inotropes 57 (2.2%) 26 (3.4%) .065
IABP 14 (0.5%) 7 (0.9%) .370
Transfused patients 549 (21.2%) 189 (24.6%) .041
CK-MB peak 38.8 59.0 34.6 46.7 .089
ICU stay (h) 22.2 21.6 20.8 24.4 .142
Hospital stay (d) 5.7 5.2 5.4 4.9 .123
AMI, Acute myocardial infarction; IABP, intra-aortic balloon pump; CK-MB,
creatine kinase muscle and brain; ICU, intensive care unit.
TABLE 2. Operative data according to groups ND and D
Group ND
(n  2593)
Group D
(n  767) P value
CPB 1699 (65.5%) 482 (62.8%) .174
Anastomoses/patient 2.6 1.1 2.6 1.0 .949
LITA 2351 (90.7%) 717 (93.5%) .015
RITA 1210 (46.7%) 352 (45.9%) .707
RGEA 359 (13.8%) 97 (12.6%) .395
RA 200 (7.7%) 53 (6.9%) .459
IEA 107 (4.1%) 18 (2.3%) .022
SVG 1045 (40.3%) 326 (42.5%) .276
BITA 1178 (45.4%) 346 (45.1%) .876
SVG to LAD 230 (8.9%) 53 (6.9%) .086
TAMR 1093 (42.2%) 308 (40.2%) .325
LITA, Left internal thoracic artery; RITA, right internal thoracic artery; RGEA, right gastroepiploic artery; RA, radial artery; IEA, inferior epigastric artery;
BITA, bilateral internal thoracic artery; TAMR, total arterial myocardial revascularization.
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0.4%, 94.9%  0.9% in group D and 96.6%  0.4% in
group ND (P  .0155, Figure 2). The results of Cox
analysis are also shown in Table 5. Now diabetes is again a
risk factor for increased incidence of cardiac deaths. Inter-
estingly, the use of saphenous vein graft (SVG) on the left
anterior descending artery (LAD) appeared as a new risk
factor, emphasizing a direct effect of this graft on late
cardiac mortality.
Late Actuarial Survival of Patients Who Survived for
30 Days
Five-year actuarial survival, with the exclusion of the first
month, was 95.7%  0.4%, 95.6%  0.9% in group D and
95.7%  0.5% in group ND (Figure 3, P  .3642). Results
of Cox analysis are shown in Table 6.
Freedom from cardiac death was 97.8%  0.3%, 97.3%
 0.8% in group D and 97.9% 0.4% in group ND (Figure
4, P  .2389). Results of Cox analysis are also shown in
Table 6. Diabetes was no longer a risk factor once patients
who died in the first 30 days were excluded.
Results According to Preoperative Treatment
The preoperative treatment of diabetes did not affect early
mortality (group OT, 18/596 [3.0%]; group IT, 7/171
[4.1%]). Five-year survival was also similar (94.64% 
1.8% in group IT vs 92.0%  1.3% in group OT, P 
Figure 1. Five-year actuarial survival (first month included): group D (solid line) versus group ND (dashed line).
TABLE 4. Stepwise logistic regression: Independent risk factors for increased early mortality, any death, and cardiac
deaths
Variable
Any death Cardiac deaths
All patients, OR
(95%CL)
Group D, OR
(95%CL)
Group ND,
OR (95%CL)
All patients, OR
(95%CL)
Group D, OR
(95%CL)
Group ND,
OR (95%CL)
Untouchable ascending aorta 2.9 (1.3-6.8) P  .0116 2.1 (0.5-8.3) 3.5 (1.2-10.3) 1.9 (0.8-4.2) P  .1545 1.7 (0.5-6.2) 2.0 (0.7-6.0)
Carotid disease 2.1 (1.2-3.7) P  .0107 1.5 (0.6-4.0) 2.2 (1.1-4.4) 1.2 (0.7-2.0) P  .3324 1.2 (0.5-2.8) 1.2 (0.6-2.3)
EF 35% 2.2 (1.1-4.5) P  .0250 8.2 (0.9-3.8) 3.0 (1.3-6.9) 2.0 (1.1-3.6) P  .2598 1.6 (0.6-4.4) 2.0 (0.98-4.2)
CHF 4.2 (1.8-9.6) P  .0006 8.9 (3.0-26.9) 2.4 (0.7-8.5) 4.5 (1.7-12.1) P  .0029 1.1 (0.2-5.7) 5.5 (1.5-19.2)
Urgent 2.0 (1.2-3.2) P  .0042 2.3 (1.0-5.2) 1.7 (0.9-3.1) 2.3 (1.2-4.2) P  .0089 2.1 (0.9-4.3) 2.3 (1.0-4.9)
SVG to LAD 2.2 (1.1-4.4) P  .0168 2.8 (0.9-9.0) 2.1 (0.9-4.7) 2.8 (1.3-6.0) P  .0068 3.6 (0.5-8.9) 2.7 (1.1-6.8)
Female sex 1.4 (0.8-2.6) P  .1932 0.8 (0.3-2.0) 2.3 (1.2-4.6) 0.9 (0.6-1.6) P  .2482 0.7 (0.3-1.6) 2.5 (1.1-5.8)
CRF (cr  2.0 mg/dL) 1.1 (0.2-4.9) P  .9251 0.8 (0.4-1.1) 4.4 (1.3-15.5) 3.8 (0.6-9.0) P  .2571 0.9 (0.8-7.9) 5.3 (1.2-24.2)
Previous AF 1.6 (0.4-2.6) P  .1932 3.2 (0.5-21.4) 0.8 (0.1-7.2) 1.9 (0.7-5.0) P  .2598 9.0 (1.7-45.8) 1.7 (0.5-6.2)
Age 75 y 1.5 (0.7-2.9) P  .4602 2.9 (0.9-8.7) 1.0 (0.4-2.6) 2.4 (1.1-5.1) P  .0223 5.7 (1.9-17.1) 1.03 (0.5-2.2)
Diabetes 1.4 (0.8-2.4) P  .1803 – – 2.0 1.1-3.7) P  .0320 – –
HR, Hazard ratio; CL, confidence limit; EF, ejection fraction; AMI, acute myocardial infarction; CHF, chronic heart failure; CRF, chronic renal failure; AF, atrial
fibrillation.
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.1850), as was freedom from cardiac death after 5 years
(97.1%  1.3% in group IT vs 94.4%  1.1% in group OT,
P  .1225).
Analyzing the patients who survived 30 days, 5-year
survival was not significantly better in group IT (98.6% 
1.0%) than in group OT (94.8%  1.1%), even if Cox
analysis did not confirm this hypothesis. Freedom from
cardiac-related death was not different in either group
(99.4%  0.6% in group IT vs 96.7%  0.9% in group
OT).
There were no statistically significant differences in
short- or long-term mortality for diabetic patients treated
perioperatively with insulin versus those who were not.
Results According to Perioperative Surgical Strategy
Tables 7 and 8 show 10-year survival and 10-year freedom
from cardiac death according to some technical variables
used during the procedure. Even if there is an evident
benefit at the univariate analysis in using extensive arterial
grafting, the Cox analysis failed to confirm this hypothesis.
Only the use of SVG on LAD was a risk factor for increased
incidence of cardiac deaths with and without the exclusion
of the first month (Tables 5 and 6).
Discussion
Because morbidity and mortality caused by ketoacidosis
and infections have a low incidence, coronary artery disease
Figure 2. Five-year freedom from cardiac death (first month included): group D (solid line) versus group ND (dashed
line).
TABLE 5. Cox analysis: Independent risk factors for increased mortality, any death, and cardiac deaths
Variable
Any death Cardiac deaths
All patients, HR
(95%CL)
Group D, HR
(95%CL)
Group ND, HR
(95%CL)
All patients, HR
(95%CL)
Group D, HR
(95%CL)
Group ND, HR
(95%CL)
Age 1.0 (1.01-1.04) P  .0003 1.0 (0.97-1.04) 1.04 (1.01-1.06) 1.0 (1.0-1.05) P  .0061 1.0 (0.97-1.06) 1.03 (1.01-1.06)
EF 35% 2.3 (1.5-3.5) P  .0001 1.8 (0.8-3.9) 2.6 (1.6-4.3) 2.3 (1.3-4.0) P  .0025 1.7 (0.6-4.7) 2.3 (1.2-4.5)
Previous AMI 1.4 (1.1-1.9) P  .0138 1.2 (0.7-2.2) 1.5 (1.1-2.1) 1.2 (0.8-1.8) P  .2448 1.4 (0.7-2.8) 1.2 (0.8-1.8)
CHF 2.1 (1.2-3.8) P  .0095 4.5 (1.9-10.5) 1.6 (0.7-3.5) 1.9 (0.8-4.1) P  .1192 1.6 (0.4-7.1) 2.1 (0.8-5.4)
CRF (cr  2.0 mg/dL) 3.9 (2.1-7.2) P  .0001 1.0 (0.1-1.3) 5.6 (2.9-10.8) 5.8 (2.8-12.0) P  .0001 1.7 (0.2-13.4) 7.8 (3.5-17.4)
Urgent 1.4 (1.1-1.9) P  .0158 2.1 (1.2-3.5) 1.3 (0.9-1.8) 1.6 (1.1-2.3) P  .0132 2.4 (1.3-4.6) 1.4 (0.9-2.2)
Peripheral vasculopathy 1.6 (1.1-2.3) P  .0153 1.9 (1.0-3.6) 1.4 (0.8-2.3) 1.2 (0.9-2.0) P  .5909 1.1 (0.5-2.8) 1.2 (0.6-2.3)
SVG to LAD 1.4 (0.9-2.0) P  .0868 1.8 (0.9-3.4) 1.3 (0.8-2.0) 2.0 (1.3-3.2) P  .0021 1.9 (0.8-4.7) 2.0 (1.2-3.4)
Diabetes 1.3 (0.9-1.7) P  .1166 – – 1.6 (1.1-2.3) P  .0180 – –
HR, Hazard ratio; CL, confidence limit; EF, ejection fraction; AMI, acute myocardial infarction; CHF, chronic heart failure; CRF, chornic renal failure.
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assumes a larger responsibility as a cause of death in dia-
betic patients.28,29 The overall prevalence of coronary
disease is as high as 55% among adult diabetic patients
compared with 2% to 4% for the general population.30 In a
large autopsy study 91% of the patients with adult diabetes
and no known coronary artery disease had severe nar-
rowing of at least one major coronary artery, and 83%
had severe 2- or 3-vessel involvement.31 The relative risk
of myocardial infarction is 50% greater in diabetic men
and 150% greater in diabetic women. Similarly, diabetic
men have sudden death 50% more often and diabetic
women 300% more often than do their age-matched
nondiabetic counterparts.32 The mortality for myocardial
infarction is higher than in nondiabetic patients33,34
with35 or without36,37 thrombolytic therapy. Furthermore,
the presence of diabetes mellitus is an independent pre-
dictor of cardiac mortality, which ranges from 26% to
62% in the first year after myocardial infarction and can
reach 79% by 5 years.38,39
Diabetic patients with multivessel coronary disease who
undergo myocardial revascularization, both surgical and
interventional, are considered at high risk for early and late
death.1-11 Because other reports were not in agreement with
these findings,15-22 we tried to find a personal answer to this
problem by analyzing our database, which included patients
operated on during 12 years.
The analysis of 30-day mortality showed that diabetes is
a univariate risk factor for higher early mortality, but mul-
tivariable analysis rejected this hypothesis. Analysis of a
large cohort of patients in a New York State database found
that diabetes was a risk factor in 2 different periods: 1992 to
1995 and 1996.11,12 This finding was confirmed by others.7,8
Figure 3. Five-year actuarial survival (first month excluded): group D (solid line) versus group ND (dashed line).
TABLE 6. Cox analysis: Independent risk factors for increased late mortality (first month excluded), all causes and cardiac
causes
Variable
Any death Cardiac deaths
All patients, HR
(95%CL)
Group D, HR
(95%CL)
Group ND, HR
(95%CL)
All patients, HR
(95%CL)
Group D, HR
(95%CL)
Group ND, HR
(95%CL)
Age 1.03 (1.01-1.05) P  .0025 1.0 (0.96-1.04) 1.04 (1.01-1.06) 1.02 (0.9-1.1) P  .0581 1.0 (0.94-1.05) 1.03 (0.98-1.07)
EF 35% 2.7 (1.6-4.5) P  .0001 2.9 (1.1-7.7) 2.7 (1.5-5.0) 2.8 (1.4-5.8) P  .0033 2.9 (0.8-10.6) 2.6 (1.1-6.1)
Previous AMI 1.5 (1.0-2.1) P  .0327 1.1 (0.5-2.4) 1.6 (1.1-2.5) 1.4 (0.8-2.3) P  .1982 1.7 (0.6-4.8) 1.2 (0.7-2.3)
CRF  2.0 mg/dL 5.9 (2.8-12.3) P  .0001 3.7 (0.5-28.4) 6.9 (3.1-15.3) 11.1 (4.7-26.1) P  .0001 3.9 (0.8-5.5) 13.2 (5.0-34.3)
Peripheral vasculopathy 1.7 (1.1-2.8) P  .0226 3.0 (1.4-6.5) 1.3 (0.7-2.4) – 2.0 (0.7-6.2) 0.9 (0.3-2.4)
SVG-LAD 1.1 (0.7-1.8) P  .5786 1.1 (0.4-3.2) 1.1 (0.7-1.9) 1.8 (1.0-3.1) P  .0484 1.3 (0.4-4.3) 1.9 (1.0-3.7)
HR, Hazard ratio; CL, confidence limit; EF, ejection fraction; AMI, acute myocardial infarction; CRF, chronic renal failure.
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However, other reports failed to identify diabetes as a risk
factor in the general population18-20,22 or in the elderly.21
In our opinion 30-day mortality is influenced by techni-
cal details more than by the disease itself. Even if no
surgical aspect was able to influence the 30-day outcome in
diabetic patients, some aspects allowed a reduction of mor-
tality more in group D than in group ND. Use of SVG on
LAD in group D was related to high mortality (4/53
[7.5%]); on the contrary, when the left internal thoracic
artery was used, the mortality showed a 2.6-fold reduction
(21/714 [2.9%]). The same aspect allowed a minor reduc-
tion in group ND (from 3.0% to 1.8%, 1.7-fold). The huge
Figure 4. Five-year freedom from cardiac death (first month excluded): group D (solid line) versus group ND (dashed
line).
TABLE 7. Ten-year (first month included) survival according to same surgical aspects (univariate analysis)
All patients Group D Group ND
N Survival P value N Survival P value N Survival P value
ITA to LAD* 2973 88.8 1.4 .0927 690 87.5 3.3 .1821 2283 89.3 1.5 .1968
SVG to LAD 283 84.9 2.3 53 79.0 6.6 230 86.1 2.4
LITA  SVG (s) 667 88.8 1.8 171 90.9 3.6 496 88.7 2.0
BITA  SVG (s) 1137 94.7 0.8 .1999† 276 93.3 1.7 .9345 861 95.2 0.9 .3166
TAMR 1401 92.5 1.2 .5093† 308 85.5 5.6 .6879 1093 93.9 0.9 .3462
2ACs  SVG (s) 1855 92.6 1.0 .5635† 420 86.4 4.9 .6587 1435 93.8 0.8 .3537
CPB‡
With 1275 93.2 0.9 .9924 343 91.1 2.0 .7640 932 93.9 1.0 .9341
Without 1214 94.1 0.9 293 93.1 1.6 914 94.4 1.0
CPL§
Crystalloid 269 91.1 1.7 40 90.0 4.7 229 90.4 1.9
Cold blood 288 92.3 1.6 .7790 48 95.7 2.9 .8058 240 91.6 1.8 .8564
Warm blood 1617 92.2 0.9 .7261 394 89.7 2.2 .9055 1223 93.0 0.9 .8716
All intermittent antegrade; no statistical difference was present when comparing groups. ITA, Internal thoracic artery; BITA, bilateral internal thoracic
artery; TAMR, total arterial myocardial revascularization; CPL, cardioplegia.
*With or without SVG, other arterial conducts, or both.
†P value versus LITA  SVG(s).
‡Five-year survival.
§Eight-year survival.
P value versus crystalloid.
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application of the non-CPB strategy reduced the early mor-
tality from 4.0% to 2.0% in group D (2-fold) and from 2.1%
to 1.5% in group ND (1.4-fold). Cumulating all these small
and apparently not influential improvements, diabetic pa-
tients are no longer at higher risk for 30-day mortality.
However, if only cardiac mortality in considered, diabe-
tes appears to have a significant influence on early outcome
because the relative incidence of cardiac deaths is higher in
group D than in group ND. The anatomic aspect of the
disease (diffuse coronary disease, small vessels, and diffuse
calcifications) can explain a higher cardiac mortality.
Late survival, including 30-day mortality, showed, at
univariate analysis, that diabetes was a risk factor, but the
Cox analysis did not confirm this finding. Excluding 30-day
mortality, diabetes was not a risk factor at either univariable
or multivariable analysis.
When only cardiac deaths were considered, diabetes was
a risk factor both at the univariable and multivariable anal-
ysis for increased early cardiac mortality and for reduced
life expectancy as a result of cardiac death. However, when
the analysis included only the patients who survived 30
days, diabetes disappeared as a risk factor both at univari-
able and multivariable analysis, showing that the influence
of diabetes on survival without cardiac death is mainly
expressed during the first postoperative month.
Other reports show clearly that diabetes is an important
risk factor for late survival. Herlitz and colleagues6 showed
that real 2-year survival was 86.1% in diabetic and 93.5% in
nondiabetic patients (P  .0001). At the multivariable anal-
ysis, diabetes had a relative risk of 1.7. Morris and cowork-
ers40 reported a 5-year survival of 80% in diabetic patients
and 91% in nondiabetic patients and an 8-year survival of
66% and 84%, respectively (P  .0001). Diabetes was an
independent risk factor with a P value of .0001. Smith and
associates41 showed a 15-year survival of 40% in diabetic
and 60% in nondiabetic patients. Diabetes was a strong
independent risk factor (P  .0001) but only in the late
phase (1 year after the operation). The same findings were
confirmed by other studies.8-10 Diabetes was rarely not
recognized as an independent risk factor for late survival,
often only in subgroups of patients.19 When freedom from
cardiac death was considered, diabetes was again a risk
factor. Pick and colleagues9 found that diabetes was an
independent risk factor both for 10-year overall (risk hazard
ratio, 2.94) and cardiac (hazard ratio, 1.73) mortality. Glo-
bally, diabetes was a risk factor in the late period, starting
the first year after the procedure.
Our findings are in contrast with those in many of the
published studies on this topic. Logically, if diabetic pa-
tients in the general population have higher mortality than
nondiabetic patients as a result of cardiac causes, it is
reasonable that a diabetic patient who undergoes myocardial
revascularization has a life expectancy better than that of a
nonoperated patient and similar to that of a nondiabetic
patient. Even if diabetes was a risk factor for higher cardiac
5-year mortality, this finding was the consequence of a
higher early cardiac mortality (2.2% in group D vs 1.1% in
group ND, P  .016) and not of a late higher mortality.
TABLE 8. Ten-year (first month included) freedom from cardiac death according to same surgical aspects (univariate
analysis)
All patients Group D Group ND
N Survival P value N Survival P value N Survival P value
ITA to LAD* 2973 93.8 1.0 .0041 690 90.5 3.3 .1954 2283 94.6 1.0 .0072
SVG to LAD 283 88.3 2.1 53 82.3 6.5 230 89.5 2.1
LITA  SVG 667 93.7 1.3 171 93.1 3.5 496 93.9 1.5
BITA  SVG 1137 97.6 0.5 .0642† 276 95.3 1.5 .5616 861 98.3 0.5 .0155
TAMR 1401 93.7 2.3 .1640† 308 90.2 5.6 .5898 1093 94.4 0.9 .1077
2 ACs  SVG 1855 94.2 1.5 .8697† 420 91.1 3.6 .7140 1435 95.0 2.7 .1092
CPB‡
With 1275 96.2 0.7 .3171 343 93.9 1.8 .2766 932 97.1 0.7 .1937
Without 1214 95.8 0.9 293 95.3 1.4 921 96.0 1.0
CPL§
Crystalloid 269 93.2 1.5 40 90.0 4.7 229 94.7 1.3
Cold blood 288 94.7 1.3 .5298 48 97.8 2.2 .5543 240 94.1 1.5 .6785
Warm blood 1617 95.1 1.1 .5588 394 94.0 1.5 .4097 1223 95.6 1.2 .7456
All intermittent antegrade; no statistical difference was present when comparing groups. ITA, Internal thoracic artery; BITA, bilateral internal thoracic
artery; TAMR, total arterial myocardial revascularization; CPB, cardiopulmonary bypass; CPL, cardioplegia.
*SVG, other arterial conducts, or both.
†P value versus LITA  SVG(s).
‡Five-year survival.
§Eight-year survival.
P value versus crystalloid.
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In fact, survival from surgical intervention was not found
to be different for diabetic versus nondiabetic patients who
survived to 1 month. The preoperative treatment of diabetic
patients did not influence the outcome. Surprisingly, insu-
lin-treated patients showed a high long-term survival
(94.6% by 5 years).
Perhaps long-term treatment with insulin, because antidi-
abetic centers are widely diffused, can better control hyper-
glycemia, lowering the complication rate in the long term.
However, the sample size is small, and definitive conclu-
sions can not be drawn.
Our analysis was not able to show improvement related
to any technical aspect during the operation. Early and late
outcomes of diabetic patients were not influenced by use of
SVG on LAD. Conversely, nondiabetic patients were influ-
enced by use of SVG on LAD only in the analysis of
freedom from cardiac death, both early and late, with or
without the inclusion of the first month.
This is in contrast with other reports9,15,42 that show a
better outcome in diabetic patients if a single or a double
internal thoracic artery is used. We were not able to find any
benefit with the use of bilateral internal thoracic arteries in
nondiabetic patients, and the use of left internal thoracic
arteries to LAD demonstrated an advantage only for cardiac
deaths. This is not easy to explain. We think that the patency
rate of the SVG in the 1990s is perhaps better than the
patency rate of the SVG in the 1980s. Worldwide use of
antiplatelet agents, as well as statins, can contribute to this
theoretic benefit. Moreover, the mean follow-up in our
series is shorter than in other reports,9,42 and some authors40
did not use a multivariable analysis to demonstrate their
hypothesis.
The similar late outcome in diabetic and nondiabetic
patients after a mean follow-up of 50 months suggests that
the effect of surgical intervention in diabetic patients is
striking. The huge cardiovascular mortality is highly re-
duced after myocardial revascularization, and the risks of
myocardial infarction with the related mortality are also
reduced. However, the incidence of cardiac deaths remains
higher than that in nondiabetic patients, although this find-
ing is limited to the first 30 days after the operation. The
price to pay for diabetes seems today smaller than in the
past.
One must take care with interpretations of subgroup
analyses. Lack of statistical significance might simply be a
lack of statistical power because of the reduced sample size.
Statistical significance might be due to spurious results,
which are expected with multiple comparisons.
In multivariable models one must remember that not
only the factors in the model but the factors in the univari-
able analyses were considered. Therefore any borderline
statistical result should be considered especially explor-
atory.
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APPENDIX. List and definition of variables
Preoperative
Age Continuous (y)
Age 75 y Dichotomous
Sex Dichotomous
Body weight Kilograms
History of hypertension Need of medical treatment (Ca2 blockers, -blockers, angiotensin-converting
enzyme inhibitors)
History of smoking More than 10 cigarettes a day smoked at least for 10 y
Hypercholesterolemia Historical or at-present cholesterol value 200 mg/dL
Chronic renal failure Creatinine value 2.0 mg/dL
Chronic hepatic failure Bilirubin value 2.0 mg/dL
Chronic obstructive pulmonary disease FEV1 less than 75% of predicted value, air PO2 lower than 60 mm Hg or chronic
medical treatment
Unstable angina Presence of angina at rest, stable angina with worsening pattern, or de novo angina.
Chronic heart failure Heart failure in the history or at the present admission without angina
Acute myocardial infarction 24 h Acute myocardial infarction 24 hours before surgical intervention
Preoperative intra-aortic balloon pump Use of intra-aortic balloon pump to stabilize unstable angina
Previous atrial fibrillation Dichotomous
Not elective operation Any condition (eg, unstable angina, cardiogenic shock, critic left main stenosis) that
avoids discharge from the hospital
Diabetes Medical treatment for hyperglycemia at rest
Insulin treatment Insulin-dependent diabetes
Oral treatment Diabetes on oral treatment
Ventricular arrhythmia In history or requiring medical treatment at this admission
Peripheral vasculopathy Symptoms or angiographic or echocardiographic evidence of dilation or reduction of
flow (stenosis or occlusion) of any artery, with the exclusion of carotid arteries
Carotid disease Presence of a fibrocalcific plaque with a stenosis 50% or of a soft plaque
conditioning any degree of stenosis
Previous CVA History of previous CVA with or without persistent neurologic defect
Previous acute myocardial infarction Electrocardiographic sign of myocardial infarction or documented non-Q infarction
Left main stem lesion Stenosis 50%
Ejection fraction Continuous
Ejection fraction 35% Dichotomous
Nitroglycerin e.v. Need of nitroglycerin e.v. at the admission in operating room
Perioperative
Use of CPB Dichotomous
Normothermic perfusion Perfusion temperature 34°C
Use of SVG on LAD Dichotomous
Use of bicaval internal thoracic artery Dichotomous
Use of only arteries Dichotomous
Simultaneous carotid surgery Dichotomous
Untouchable ascending aorta Severe atherosclerotic or calcified aortic wall not eligible for clamping or
manipulation detected before the operation or when the chest was open
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